fda warning letters compounded semaglutide 2025 september Concerns Surrounding GLP-1s Mount As Shortages of Tirzepatide, End A company called Nomida has

Ensuring adherence to appropriate handling and administration protocols is critical, especially concerning injectable medications, making knowledge from a course on Safe Prescribing highly relevant

Misbranding a drug in interstate commerce is a prohibited act and can result in regulatory and/or legal enforcement actions, including the issuance of an untitled letter or warning letter, injunctions, or in extreme instances, criminal prosecution

Weight Loss Drugs in Development Doctors are studying new treatment strategies to help people lose weight and to stay at a healthy weight

There Is Now a GLP-1 Pill On April 1, 2026, the FDA approved orforglipron (Foundayo) from Eli Lilly

Patients allergic to any of the active ingredients or manufacturing material in the patch may experience allergic reactions

The medication is administered through a weekly subcutaneous injection